Qianjiang Yongan Pharmaceutical Co Ltd

The company maintains a strong liquidity position, with a current ratio of 5.65, indicating a robust ability to meet short-term obligations. However, its net cash position is negative after subtracting total debt, signaling potential liquidity risk. The debt-to-equity ratio is low at 0.01, suggesting minimal leverage and a conservative capital structure. Free cash flow stands at 31.87 million CNY, but capital expenditures are negative at -62.28 million CNY, indicating asset disposals or reduced investment in physical infrastructure. Profitability metrics show a return on equity (ROE) of 1.13% and a return on assets (ROA) of 1.02%, both below the typical thresholds for high-performing pharmaceutical firms. Gross profit of 131.08 million CNY represents 16.74% of total revenue, which is in line with industry norms but does not suggest a competitive margin advantage. Operating income of 10.46 million CNY and net income of 22.49 million CNY indicate modest profitability, with a net margin of 2.87%. The company's revenue is not segmented by product or geographic region in the available data, making it difficult to assess revenue concentration or diversification. However, the absence of disclosed geographic breakdowns suggests a likely domestic focus, which could expose the company to regulatory and economic risks specific to China. Recent revenue of 783.17 million CNY is below the analyst estimate of 1.16 billion CNY, indicating a potential shortfall in performance expectations. The outlook for the current fiscal year is not explicitly provided, but the negative variance from estimates suggests a need for performance improvement. The company's capital expenditures are negative, which may signal a strategic shift or reduced investment in growth. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's low debt-to-equity ratio and strong current ratio support the low dilution risk, but the negative net cash position introduces a liquidity concern. No recent filings or transcripts are available to provide additional context on strategic or operational developments.